Follow
Immuno-mediated Diseases
Immuno-mediated diseases are characterized as conditions or disorders caused by abnormal immune cells. Immune cells work by identifying and eliminating foreign invaders in the body, such as cancer or infected cells. In cases where immune cells become overactive or mistakenly attack their own cells a variety of conditions can occur. Examples of immuno-mediated diseases include systemic lupus erythematous (SLE) and rheumatoid arthritis (RA), and type 1 diabetes.
FEB 23, 2022 | 1:30 PM
High-throughput sequencing technology such as RNASeq and whole genome sequencing has enabled deep characterization of health and disease states. Biomarker discovery by these means has only h...
FEB 23, 2022 | 6:00 AM
Cancer still accounts for nearly 1 in every 4 deaths worldwide. New immunotherapies have the power to induce durable responses in patients with fatal cancers, but only a small percentage of...
DEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...
FEB 10, 2021 | 8:00 AM
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
OCT 07, 2020 | 10:30 AM
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
SEP 19, 2019 | 8:00 AM
Learning Objectives: Review basic immuno-pathobiology of IBD and the phenotypes of IBD or IBDs - Crohn’s, Ulcerative Colitis and Indeterminate Colitis Briefly describe the epide...
OCT 11, 2018 | 12:00 PM
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
OCT 11, 2018 | 9:00 AM
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
AUG 16, 2018 | 8:00 AM
DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
DEC 09, 2021 | 8:00 AM
Date: December 9, 2021 Time: 8:00am (PDT), 11:00am (EDT) Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donorderived human leukocyte antigen (H...
FEB 10, 2021 | 8:00 AM
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
OCT 07, 2020 | 10:30 AM
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...